text
stringlengths 0
197k
|
|---|
H0.2. Applying buzzy during the vascular access procedure has no effect on children's pain and anxiety levels. |
H0.3. Listening to a music video + applying buzzy during the vascular access procedure has no effect on children's pain and anxiety levels. conditions: Pain conditions: Anxiety conditions: Nurse's Role studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: It is a randomized controlled experimental study. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 126 type: ACTUAL name: Buzzy name: Music video listening name: Buzzy+ Music video listening measure: Wong-Baker Facial Expression Rating Scale measure: Children's Fear and Anxiety Scale sex: ALL minimumAge: 4 Years maximumAge: 12 Years stdAges: CHILD facility: Bircan Kahraman Berberoğlu city: Aydın state: AYDIN-efeler zip: 0900 country: Turkey lat: 37.84501 lon: 27.83963 hasResults: False |
<|newrecord|> nctId: NCT06370104 id: NL85041.018.23 briefTitle: Treating Suicidality Remotely acronym: TREASURE overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2028-04-25 date: 2028-04-25 date: 2024-04-17 date: 2024-04-17 name: 113 Suicide Prevention class: OTHER name: Amsterdam UMC briefSummary: Background: Practical and psychological barriers make it difficult for people with Suicidal Thoughts and Behaviors (STBs) to get professional help. Online interventions have the potential to overcome many of these barriers, but the online interventions to date have produced small or short-lived effects and have only been found to reduce suicidal thoughts, not behaviors. This is a crucial limitation, since previous studies have shown that interventions that reduce suicidal thoughts often do not prevent suicide attempts, and vice versa. |
Methods: A fully remote randomized controlled trial will be conducted in which 364 participants of 16 years and older will be recruited through the website of a suicide prevention helpline in the Netherlands and randomized with an allocation ratio of 1:1 to either Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT-SP) or a semi-guided online self-help course that has previously been found superior to waitlist in reducing suicidal thoughts. The primary outcome of the study is the number of suicide attempts, measured with the Columbia Suicide Severity Rating Scale. Secondary outcomes are self-reported suicidal ideation, healthcare utilization, treatment satisfaction, adverse effects, and quality of life. All outcomes will be assessed at baseline, immediately after the treatment and at 18 months follow-up. |
Discussion: If remote BCBT-SP proves effective, the findings of this study will add to the evidence base of BCBT-SP as one of very few psychological interventions with replicated effectiveness in preventing suicide attempts and provide the first evidence to date that remote interventions cannot only reduce suicidal thoughts, but also prevent suicidal behavior. conditions: Suicide Attempt studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel randomized controlled trial with a 1:1 allocation ratio. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Participants are not blind to the treatment condition, but are unaware which is the experimental condition and which the control condition. whoMasked: OUTCOMES_ASSESSOR count: 364 type: ESTIMATED name: Brief Cognitive Behavioral Therapy for Suicide Prevention name: Living under control measure: Number of suicide attempts measure: Severity of suicidal ideation measure: Severity of suicidal Thoughts and Behaviors Composite measure: Treatment satisfaction measure: Adverse effects measure: Co-occuring mental health issues measure: Quality of life sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: 113 Suicide Prevention city: Amsterdam state: Zuid-Holland zip: 1105BP country: Netherlands name: Wilco Janssen, MSc role: CONTACT phone: 020 3 113 883 email: [email protected] name: Saskia Mérelle, PhD role: CONTACT phone: 020 3 113 883 email: [email protected] lat: 52.37403 lon: 4.88969 hasResults: False |
<|newrecord|> nctId: NCT06370091 id: PICVII19-41 briefTitle: Effect of Xylitol-based Chewing Gums, Sugar-free and Sugared, on Salivary Flow and pH in Young Adults overallStatus: RECRUITING date: 2023-12-12 date: 2024-05-31 date: 2024-07-31 date: 2024-04-17 date: 2024-04-24 name: Universidad Católica de Cuenca class: OTHER briefSummary: This study was planned to evaluate the effects of xylitol-based chewing gums, sugar-free and sugared, on salivary flow and pH in young adults. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: It will be an experimental study through a double-blind parallel randomized controlled trial. |
All saliva samples will be collected using the spitting method. Each participant will provide a basal saliva sample for 5 minutes. Participants must meet the following inclusion criteria: having at least 20 teeth, providing written informed consent, and being willing to comply with the study procedures. The exclusion criteria will include individuals with systemic, infectious, or inflammatory diseases or those taking medications, antibiotics, or fluoride in the last month; regular consumers of products and mouthwashes containing xylitol or sorbitol, with abnormal salivary flow (\<1 ml/min), pregnant women or those on contraceptive pill treatment, or with abnormal dietary habits; subjects with periodontal disease or presence of dental caries primaryPurpose: OTHER masking: DOUBLE maskingDescription: Participants who meet the selection criteria will be probabilistically assigned using simple random sampling through a lottery system. An urn will be used to draw colors corresponding to a type of chewing gum whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 100 type: ESTIMATED name: Gum of Xylitol name: Gum of sugar free name: Gum of sugar name: Paraffin wax measure: G1: Gum of xilytol measure: G2: Gum of sugar free measure: G3: Gum of sugar measure: G4: Parafinn wax sex: ALL minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Miriam Lima status: RECRUITING city: Cuenca state: Azuay zip: 010101 country: Ecuador name: Miriam Lima, Ph D role: CONTACT phone: 0999975073 email: [email protected] lat: -2.90055 lon: -79.00453 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-12-12 uploadDate: 2024-04-13T10:26 filename: Prot_000.pdf size: 1132158 hasResults: False |
<|newrecord|> nctId: NCT06370078 id: Ahmed Helal briefTitle: Effect of Early Administration of Albumin 20% Versus Crystalloid overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-11-01 date: 2025-11-15 date: 2024-04-17 date: 2024-04-17 name: Egymedicalpedia class: INDUSTRY briefSummary: Sepsis and septic shock are global health problems, leading to a high mortality rate. They are often associated with extremely low blood pressure and multiple organ dysfunctions, which are the main causes of death in critically ill patients. Fluid resuscitation is one of the most critical treatments for patients with sepsis and septic shock. |
An early administration of an appropriate fluid to patients is considered the most effective way to increase blood pressure, improve tissue perfusion, and save their lives. Crystalloid fluids are a subset of intravenous solutions composed of mineral salts and other small, water-soluble molecules, including normal, isotonic or hypertonic saline, and various buffered solutions. conditions: Septic Shock studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 46 type: ESTIMATED name: Albumin Human measure: Recovery from shock sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Assuit University hospitals city: Assiut country: Egypt name: Ahmed Abdelhamed Helal Mohamed, MSc role: CONTACT phone: +201140415513 email: [email protected] name: Amany Hassan Abdelwahab, Assist.Prof. role: CONTACT phone: +201004610623 email: [email protected] name: Noha Yahia Mohamed, Lecturer role: PRINCIPAL_INVESTIGATOR lat: 27.18096 lon: 31.18368 hasResults: False |
<|newrecord|> nctId: NCT06370065 id: HLX10IIT70-TJ briefTitle: Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients overallStatus: RECRUITING date: 2023-04-27 date: 2024-06-30 date: 2024-12-31 date: 2024-04-17 date: 2024-04-17 name: Tianjin Medical University Cancer Institute and Hospital class: OTHER briefSummary: Evaluation of the efficacy and safety of Serplulimab combined with bevacizumab biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) patients conditions: Advanced Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04） measure: ORR measure: PFS measure: OS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tianjin Cancer Hospital Airport Hospital status: RECRUITING city: Tianjin state: Tianjin country: China name: Huikai Li, MD role: CONTACT lat: 39.14222 lon: 117.17667 hasResults: False |
<|newrecord|> nctId: NCT06370052 id: CHCRI-DJ-HS briefTitle: Pathophysiological Basis of Hidradenitis Suppurativa overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-31 date: 2026-12-31 date: 2024-04-17 date: 2024-04-17 name: Clinical Hospital Center Rijeka class: OTHER briefSummary: HS is a chronic inflammatory disease manifested by recurrent inflammatory nodules, abscesses and tunnels under the skin. This disease is characterized by an inflammatory process that takes place in hair follicles, sebaceous glands and surrounding tissue. Because of its frequent recurrence and chronicity, it represents a major public health problem and there is a need for better diagnosis and new and more effective drugs. This research can be a part of realizing the stated needs. conditions: Hidradenitis Suppurativa studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: excision measure: The pathohistological changes measure: The expression of cytokines measure: The correlation of the clinical Hurley classification and pathohistological changes sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06370039 id: INV-102-CS-003 briefTitle: Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease overallStatus: RECRUITING date: 2024-03-27 date: 2024-08 date: 2024-08 date: 2024-04-17 date: 2024-04-24 name: Invirsa, Inc. class: INDUSTRY briefSummary: Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease. conditions: Dry Eye Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 110 type: ESTIMATED name: INV-102 name: Vehicle measure: Change from Baseline in corneal fluorescein staining total score on the National Eye Institute (NEI)/Industry scale measure: Percentage of eyes with complete clearing of central corneal fluorescein staining sex: ALL minimumAge: 18 Years maximumAge: 74 Years stdAges: ADULT stdAges: OLDER_ADULT facility: iuvo BioScience status: RECRUITING city: Rush state: New York zip: 14543 country: United States lat: 42.9959 lon: -77.64556 hasResults: False |
<|newrecord|> nctId: NCT06370026 id: KSD-101-CR004 briefTitle: KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-31 date: 2026-12-31 date: 2024-04-17 date: 2024-04-17 name: Sun Yat-sen University class: OTHER name: Kousai Bio Co., Ltd. briefSummary: The main purpse of this study is to evaluate the safety of KSD-101 in patients with EBV-associated Nasopharyngeal Carcinoma,to evaluate the initial clinical outcomes and evaluate the immune response to KSD-101 for the treatment in Patients with EBV-associated Nasopharyngeal Carcinoma. conditions: Nasopharyngeal Carcinoma studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: KSD-101 measure: The incidence Adverse events (Safety endpoint) measure: EBV-DNA load measure: Objective response rate (ORR) measure: Disease control rate (DCR) measure: Duration of response (DOR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Levels of EBV-specific CD8+ T cells measure: Levels of B cells measure: Levels of NK cells measure: According to EORTC QLQ-C30 measure: According to EQ-5D-5L measure: According to EORTC QLQ-H&N35 measure: According to ECOG fitness status sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen University Cancer Center city: Guangzhou state: Guangdong zip: 510060 country: China lat: 23.11667 lon: 113.25 hasResults: False |
<|newrecord|> nctId: NCT06370013 id: TT00420US14 briefTitle: Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors overallStatus: AVAILABLE date: 2024-04-17 date: 2024-04-17 name: TransThera Sciences (Nanjing), Inc. class: INDUSTRY briefSummary: This study is an open-label, multicenter study for Continued Characterization of Safety and Tolerability of TT-00420 (tinengotinib) Tablet Monotherapy in Adult Patients with Advanced Solid Tumors conditions: Advanced Solid Tumors conditions: Cholangiocarcinoma studyType: EXPANDED_ACCESS name: Tinengotinib sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of Chicago Medical Center status: AVAILABLE city: Chicago state: Illinois zip: 60637 country: United States lat: 41.85003 lon: -87.65005 facility: Roswell Park Comprehensive Cancer Center status: AVAILABLE city: Buffalo state: New York zip: 14203 country: United States lat: 42.88645 lon: -78.87837 facility: Sarah Cannon Research Institute status: AVAILABLE city: Nashville state: Tennessee zip: 37203 country: United States lat: 36.16589 lon: -86.78444 facility: MD Anderson Cancer Center status: AVAILABLE city: Houston state: Texas zip: 77030 country: United States lat: 29.76328 lon: -95.36327 facility: UW Carbone Cancer Center status: AVAILABLE city: Madison state: Wisconsin zip: 53705 country: United States lat: 43.07305 lon: -89.40123 hasResults: False |
<|newrecord|> nctId: NCT06370000 id: MCC-23-20817 id: HM20029540 type: OTHER domain: Virginia Commonwealth University briefTitle: Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality acronym: REMAIN1 overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-10-31 date: 2028-10-31 date: 2024-04-17 date: 2024-04-17 name: Virginia Commonwealth University class: OTHER briefSummary: Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains conditions: Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Oral Azacitidine measure: Rate of completion of at least 4 cycles an oral maintenance strategy for transplant eligible AML patients in CR who are medically underserved or have a disadvantage in the CDC SDOH domains measure: Overall survival (OS) measure: Leukemia Free Survival (LFS) 3 months after beginning of treatment and at relapse, completion of treatment or removal from study measure: Measure rates of measurable residual disease (MRD) negativity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Virginia Commonwealth University city: Richmond state: Virginia zip: 23298 country: United States name: Kristin Lantis, MSN, RN role: CONTACT phone: 804-828-2177 email: [email protected] name: Massey Heme Malig Team role: CONTACT email: [email protected] name: Keri Maher, DO role: PRINCIPAL_INVESTIGATOR lat: 37.55376 lon: -77.46026 hasResults: False |
<|newrecord|> nctId: NCT06369987 id: 46238 briefTitle: Visual Performance of Dailies Total1 Multifocal and Acuvue Oasys Max 1-Day Multifocal in Presbyopic Lens Wearers acronym: GIRAFFE overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-10 date: 2024-10 date: 2024-04-17 date: 2024-04-17 name: University of Waterloo class: OTHER name: Alcon Research briefSummary: The purpose of this study is to measure the logMAR visual acuity when presbyopic soft lens wearers are fit with Dailies Total1 Multifocal and ACUVUE OASYS MAX 1-DAY Multifocal. conditions: Presbyopia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 40 type: ESTIMATED name: Deleficon A (multifocal) name: Senofilcon A (multifocal) measure: High contrast visual acuity (logMAR) at 6m measure: High contrast visual acuity (logMAR) at 40cm sex: ALL minimumAge: 42 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre for Ocular Research & Education (CORE) city: Waterloo state: Ontario zip: N2L 3G1 country: Canada name: Jill Woods, MSc, MCOptom role: CONTACT phone: 519-888-4567 phoneExt: 36746 email: [email protected] name: Lyndon Jones, PhD, FCOptom role: PRINCIPAL_INVESTIGATOR lat: 43.4668 lon: -80.51639 hasResults: False |
<|newrecord|> nctId: NCT06369974 id: 2024P000386 briefTitle: Single Participant Study of an Experimental ASO Treatment for TUBB4A-related Leukodystrophy overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2026-06 date: 2024-04-17 date: 2024-04-18 name: Massachusetts General Hospital class: OTHER name: n-Lorem Foundation briefSummary: This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single pediatric participant with TUBB4A associated leukodystrophy. conditions: Genetic Disease studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single participant interventional study primaryPurpose: TREATMENT masking: NONE maskingDescription: Open label study count: 1 type: ESTIMATED name: Antisense oligonucleotide treatment (ASO) measure: Neurological assessments measure: Feeding and swallow evaluation measure: Safety and tolerability sex: ALL minimumAge: 4 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06369961 id: TDFCANCERPAIN20230101 briefTitle: Correlation Between the Analgesic Effect of Fentanyl Transdermal Patches and Nutritional Status in Cancer Pain Patients overallStatus: COMPLETED date: 2023-03-01 date: 2023-07-31 date: 2023-12-31 date: 2024-04-17 date: 2024-04-17 name: Chongqing University Cancer Hospital class: OTHER briefSummary: The goal of this observational study is to investigate the correlation and quantitative relationship between the analgesic effect of fentanyl transdermal patches in cancer pain patients and their nutritional status. conditions: Cancer Pain conditions: Nutrition Disorders studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 151 type: ACTUAL name: transdermal fentanyl measure: 11-point numeric rating scale (NRS) after TDF treatment measure: the occasions that breakthrough pain attacks per day after TDF treatment measure: The dose adjustment of TDF measure: The kinds of other analgesics combined with TDF measure: Adverse effects sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chao Li city: Chongqing zip: 400030 country: China lat: 29.56278 lon: 106.55278 hasResults: False |
<|newrecord|> nctId: NCT06369948 id: M703 briefTitle: Quality Of Recovery After Pericapsular Nerve Group (PENG) Block For Hip Hemiarthroplasty Under Spinal Anesthesia overallStatus: RECRUITING date: 2024-03-01 date: 2024-09-01 date: 2024-09-01 date: 2024-04-17 date: 2024-04-17 name: Fayoum University Hospital class: OTHER briefSummary: Patients undergoing hip hemiarthroplasty can benefit significantly from regional anesthesia in terms of pain management and recovery . There is a wide range of regional anesthetic techniques. The most common in this anatomical region and those with the greatest published research are fascia iliac block, lumbar plexus block, and femoral nerve block . Alternative methods include lateral femoral cutaneous nerve and selective obturator nerve infiltration blocks. Novel techniques, including local infiltration analgesia and quadratus lumborum block, have been reported. |
While femoral nerve and lumbar plexus blocks are two common opioid-sparing regional anesthetic procedures that are successful, they come with a risk of undesired lower limb muscle weakness . On the other hand, the fascia iliac block does not always offer sufficient pain relief following hip surgery. The important landmarks targeted on the hip joint branches from the femoral nerve and the auxiliary obturator nerve may now be identified thanks to a recent anatomical study on hip innervation . |
This led to the discovery of a novel localized anesthetic treatment termed pericapsular nerve group block (PENG), which blocks these nerves to target the hip's anterior capsule. The PENG block has been suggested as a successful motor-sparing block for hip hemiarthroplasty . The objective of the current study is to evaluate the efficacy of the pericapsular nerve group block (PENG) for the reduction of opioid consumption and management of postoperative pain after hip hemiarthroplasty. conditions: Hip Hemiarthroplasty studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: We will include 60 patients who will undergoe elective hip hemiarthroplasty. Patients will be divided into two groups randomized by computer generated random numbers that will be placed in separate opaque envelopes that will be opened by study investigators just before the block. |
Pericapsular Nerve Group (PENG) Block (P group) includes 30 patients who will receive a PENG block. |
Control group (C group) includes 30 patients who will not receive a PENG block. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Patients will be divided into two groups randomized by computer generated random numbers that will be placed in separate opaque envelopes that will be opened by study investigators just before the block. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Pericapsular Nerve Group (PENG) Block name: elective hip hemiarthroplasty without receiving a PENG block. name: bupivacaine 0.5% injection measure: Total opioid consumption post operative measure: 2) a Visual Analogue Scale (VAS) ranging from zero (no pain) to 10 (severe pain) for dynamic and static pain measure: 3) Time to first opioid use measure: 4) Ability to perform physiotherapy measure: 5) Opioid-related side effects. measure: 6) Total length stay of hospital measure: 7) Complications of local anesthetic toxicity sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fayoum University Hospital status: RECRUITING city: Madīnat Al Fayyūm state: Fayoum Governorate zip: 63514 country: Egypt name: Atef Mohamed Sayed, MS.C role: CONTACT phone: 01003973883 email: [email protected] lat: 29.31667 lon: 30.83333 hasResults: False |
<|newrecord|> nctId: NCT06369935 id: 20240407 briefTitle: A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. overallStatus: NOT_YET_RECRUITING date: 2024-06-20 date: 2026-08-20 date: 2027-08-20 date: 2024-04-17 date: 2024-04-17 name: Peking University People's Hospital class: OTHER briefSummary: This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data conditions: Relapsed/Refractory Multiple Myeloma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 260 type: ESTIMATED name: Equecabtagene Autoleucel measure: Best Overall Response Rate， BOR measure: PFS rate of 6 month measure: OS rate of 6 month measure: Time to Response， TTR measure: Time to Complete Response， TTCR measure: Adverse Event， AE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University People's Hospital city: Beijing country: China name: Yang Liu role: CONTACT phone: +8613716926210 email: [email protected] lat: 39.9075 lon: 116.39723 hasResults: False |
<|newrecord|> nctId: NCT06369922 id: STUDY00009315 briefTitle: TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. acronym: TENSUB overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-03-31 date: 2026-06-01 date: 2024-04-17 date: 2024-04-19 name: University of Rochester class: OTHER briefSummary: This will be a double-blind randomized control trial in women with stress urinary incontinence who are undergoing an outpatient transurethral bulking procedure for stress urinary incontinence. Subjects will be identified by the University of Rochester urologists and urogynecologists participating in the study who currently oversee stress incontinence care. Subjects will be randomized into two groups. One group will be undergoing the cystoscopy with transcutaneous electrical nerve stimulation (TENS) for analgesia, and the second group will have the cystoscopy with placebo TENS. conditions: Stress Incontinence Female conditions: Urinary Incontinence conditions: Urinary Incontinence,Stress conditions: Pain conditions: Pain Acute studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: TENS name: Control TENS measure: Mean pain measured by Visual Analog Scale (VAS) measure: Mean pain measured by Visual Analog Scale (VAS) measure: Mean pain measured by Visual Analog Scale (VAS) measure: Mean pain measured by Likert scale measure: Mean pain measured by Likert scale measure: Mean pain measured by Likert scale measure: Number of participants with side effects measure: Mean satisfaction with the procedure measure: TENS or NO TENS sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pelvic Health and Continence Specialties city: Rochester state: New York zip: 14623 country: United States name: Jared M Floch, DO, MS role: CONTACT phone: 585-895-9301 email: [email protected] name: Diego Hernandez-Aranda, MD role: CONTACT phone: (585) 487-3400 email: [email protected] name: Jared M Floch, DO, MS role: PRINCIPAL_INVESTIGATOR lat: 43.15478 lon: -77.61556 hasResults: False |
<|newrecord|> nctId: NCT06369909 id: K5507 briefTitle: Study on AI-assisted Multimodal Diagnosis System of Autoimmune Pancreatitis overallStatus: RECRUITING date: 2024-01-31 date: 2025-01-31 date: 2026-01-31 date: 2024-04-17 date: 2024-04-17 name: Peking Union Medical College Hospital class: OTHER name: Tianjin Medical University General Hospital name: The Second Hospital of Hebei Medical University briefSummary: The existing comprehensive diagnostic system for autoimmune pancreatitis (AIP) is complex, with multidimensional clinical information including morphological changes and a lack of specific biomarkers. Endoscopic ultrasound (EUS) can provide all the elements for morphological diagnosis of AIP, but the long learning curve and large observer differences make it difficult to popularize and promote. The cooperation units of the three regions in this project have found in the early stage that Klebsiella pneumoniae (KP) induced follicular helper T cells (Tfh) activation is an important mechanism of AIP, but the identification of pathogenic components of the strain and clinical validation need to be explored. We have established a national multicenter AIP queue in the early stage and extracted EUS audio-visual features to establish a scoring model, but intelligent assistance is still needed to improve efficiency. Therefore, we plan to integrate gut microbiota, Tfh activation markers, and EUS imaging features to establish an AI assisted multimodal diagnostic system for AIP. This study will collaborate across multiple centers to identify and validate the components that induce Tfh activation in KP bacterial cells, to extract EUS pancreatic ultrasound features and optimize artificial intelligence assisted diagnostic algorithms, and to establish and validate an artificial intelligence assisted multimodal diagnostic system based on clinical information, biomarkers, and EUS. The aim of this study is to provide new diagnosis and treatment evaluation methods for AIP with high accuracy, convenience, and easy promotion for clinical practice. conditions: Autoimmune Pancreatitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 180 type: ESTIMATED name: EUS-FNA measure: Tfh level in blood measure: Microbiota composition measured by 16S rRNA sequencing measure: AI-EUS differentiation measure: Cytokine level in blood sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences status: RECRUITING city: Beijing state: Beijing zip: 100730 country: China name: Mai Li role: CONTACT phone: 13683296860 email: [email protected] name: Xi Wu role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False |
<|newrecord|> nctId: NCT06369896 id: SpyIDUSForNonictericStricture briefTitle: Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures acronym: Spy+IDUS overallStatus: NOT_YET_RECRUITING date: 2024-05-05 date: 2025-12-25 date: 2026-12-25 date: 2024-04-17 date: 2024-04-17 name: Soonchunhyang University Hospital class: OTHER briefSummary: This study aims to evaluate the usefulness of disposable digital single-operator cholangioscopy (SOC) and intraductal ultrasound (IDUS) for the accurate diagnosis of indeterminate biliary stricture. conditions: Cholangiocarcinoma conditions: Biliary Stricture studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 36 type: ESTIMATED measure: diagnostic accuracy of SOC measure: Diagnostic accuracy of IDUS measure: Technical success of SOC measure: Technical success of IDUS measure: Adverse event sex: ALL minimumAge: 19 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06369883 id: 2022/41 briefTitle: How Often and What Type of Deformity is Detected in All Spine Radiographs? overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-06-30 date: 2024-08-30 date: 2024-04-17 date: 2024-04-17 name: Bakirkoy Dr. Sadi Konuk Research and Training Hospital class: OTHER_GOV briefSummary: The study will be done retrospectively.The aim of this study is to retrospectively examine the spinal pathologies of patients with a prediagnosis of spinal deformity and for whom spinal radiography is requested and to evaluate the clinical features of these patients. conditions: Scoliosis conditions: Kyphosis conditions: Radiography studyType: OBSERVATIONAL observationalModel: ECOLOGIC_OR_COMMUNITY timePerspective: RETROSPECTIVE count: 632 type: ESTIMATED name: Spine radiography measure: Who should have full spine radiographs? measure: We aimed to determine the frequency of kyphosis, types and percentages of scoliosis detected on the radiographs. sex: ALL minimumAge: 1 Year maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False |
<|newrecord|> nctId: NCT06369870 id: PAINCARE briefTitle: Interpectoral-pectoserratus Plane Block for Minimally Invasive Aortic Valve Replacement Via Right Anterior Minithoracotomy acronym: PAINCARE overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2027-11 date: 2027-12 date: 2024-04-17 date: 2024-04-17 name: Algemeen Ziekenhuis Maria Middelares class: OTHER briefSummary: The goal of this clinical trial is to evaluate the analgesic effect of locoregional anaesthesia, specifically the interpectoral pectoserratus plane (IPP-PSP) block, in comparison to a placebo (sham block) after Aortic Valve Replacement via Right Anterior Minithoracotomy (AVR-RAT). The main question the trial aims to answer is: Can the IPP-PSP block effectively reduce opioid consumption within the first 48 hours after AVR-RAT surgery? The purpose is to understand the impact of the IPP-PSP block on postoperative pain. Therefore, the aim is to investigate the influence of the IPP-PSP block on the amount of pain medication administered during the patients' first 48 hours after surgery. |
Participants, who are scheduled for AVR-RAT surgery, will be randomly assigned to receive either the IPP-PSP block or the sham block. Researchers will compare opioid consumption among other outcomes, including differences in pain scores, incidence of nausea and vomiting, quality of recovery, quality of life, and the length of hospital stay between the two groups. |
Patients will be monitored during their hospitalization, and a follow-up phone call will be conducted 30 days after surgery. conditions: Analgesic Effect studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The trial is designed as a single-center, prospective, double-blind, randomized controlled superiority trial. Patients will be randomly assigned to either the IPP-PSP block group or the sham block group (placebo). primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Neither the participant, anesthesiologist, study nurse, surgeon, nor the doctors and nurses in the Intensive Care Unit will know the participant's group assignment. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 144 type: ESTIMATED name: Levobupivacaine Hydrochloride 0.25 % Injectable Solution name: Sodium chloride 0.9% measure: Cumulative opioid consumption measure: Number of episodes of postoperative pain measure: Time to need for rescue medication measure: Number of patients with respiratory complications measure: PaCO2 levels measure: Postsurgical Quality of Recovery measured by the Quality of Recovery questionnaire measure: Number of episodes of postoperative nausea and vomiting measure: Time to extubation measure: Number of hours spent in the Intensive Care Unit measure: Hospitalization duration measure: Quality of life measured by the 5 level version of the EuroQoL-5 Dimension questionnaire measure: Days alive and at home measure: Vital status (whether the patient is alive or dead) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bart Vaes city: Gent state: Oost-Vlaanderen zip: 9000 country: Belgium name: Bart Vaes, MD role: CONTACT phone: +3292461700 email: [email protected] name: Steffi Ryckaert, MSc role: CONTACT phone: +3292461910 email: [email protected] lat: 51.05 lon: 3.71667 hasResults: False |
<|newrecord|> nctId: NCT06369857 id: PPY briefTitle: Pectopexy for Apical Prolapse Management overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-02 date: 2025-08 date: 2024-04-17 date: 2024-04-17 name: Assiut University class: OTHER briefSummary: This study was designed to evaluate the efficacy of pectopexy for treatment of apical pelvic organ prolapse at follow up at 12 months. Investigator also evaluates complications, improvement of symptoms, quality-of-life outcomes and patient satisfaction with surgery. |
Assessment of restoration of normal pelvic anatomy and lower urinary tract symptoms using transperineal ultrasound conditions: Pelvic Organ Prolapse studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Case series study primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Pectopexy measure: Pelvic Organ Prolapse Quantification stage measure: Urinary Symptoms questionnaire measure: Bladder neck measurements using Transperineal US sex: FEMALE minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06369844 id: 1.2023-440 briefTitle: Pressure Injury Education Intervention for Pediatric Intensive Care Nurses: A Randomized Controlled Trial overallStatus: ENROLLING_BY_INVITATION date: 2024-04-01 date: 2024-04-03 date: 2024-04-30 date: 2024-04-17 date: 2024-04-17 name: Ankara Yildirim Beyazıt University class: OTHER name: Ankara City Hospital Bilkent briefSummary: The purpose of this observational study is to find out the impact of pressure injury education on the knowledge level of pediatric intensive care nurses and the likelihood of pediatric pressure injury occurrence. The main questions it aims to answer are: |
* Does pressure injury education increase nurses knowledge level on pediatric pressure injuries? |
* Does the rate of pediatric pressure injuries decrease after the education? |
The researcher will compare nurses working in two separate pediatric intensive care units where similar patients are treated to see if planned education on pressure injuries affects nurses knowledge level and the rate of pediatric pressure injuries. |
* Volunteer nurses participating in the study will answer pressure injury survey questions prepared by the researcher. |
* Nurses in the intervention group will attend planned education sessions provided by the researcher. |
* Two weeks after the completion of the education sessions, all nurses in the intervention and control groups who wish to continue participating in the study will answer the pressure injury survey questions prepared by the researcher again. conditions: Pressure Injury Prevention studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study design will be two-group and pretest-posttest design. primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 50 type: ESTIMATED name: Pressure injury education measure: Stop Pressure Injuries" Education Evaluation Survey sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara yıldırım Beyazıt Üniversitesi city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False |
<|newrecord|> nctId: NCT06369831 id: ABS011-1 id: 2024-511419-22-00 type: CTIS briefTitle: HER2 Targeted Molecular Imaging in mBC Using 68Ga-ABS011 acronym: HERMIA overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2025-01 date: 2025-06 date: 2024-04-17 date: 2024-04-17 name: ABSCINT NV/SA class: INDUSTRY briefSummary: This phase II study aims to confirm the diagnostic performance and accuracy of 68Ga-ABS011 PET/CT in determining the HER2 expression status, and to evaluate 68Ga-ABS011's ability to drive changes in therapeutic treatment. 68Ga-ABS011 will be compared to the current standard of care (SOCa) diagnostic methods including immunohistochemistry (IHC), in situ hybridization (ISH) and imaging tools used for treatment response follow-up including Fluorodeoxyglucose F-18 (18F-FDG) positron emitted tomography (PET) and contrast enhanced computed tomography (ceCT). conditions: Metastatic Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Interventional, prospective, single arm radio-diagnostic study. Driven by number of biopsied lesions (and not by number of patients) primaryPurpose: DIAGNOSTIC masking: NONE count: 60 type: ESTIMATED name: 68Ga-NOTA-ABSCINT-HER2 PET/CT measure: positive, negative, and overall diagnostic agreement between 68Ga-ABS011 PET/CT and the standard of care IHC (and ISH) HER2 status test. measure: Safety of 68Ga-ABS011. measure: Change in treatment management measure: reliability of whole body 68Ga-ABS011 PET/CT compared to HER2-targeted treatment response (Early tumor shrinkage) measure: reliability of whole body 68Ga-ABS011 PET/CT compared to HER2-targeted treatment response (metabolic response) measure: Tumor heterogeneity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: OLV Aalst city: Aalst state: East-Flanders zip: 9300 country: Belgium name: G. Huygh, Dr. role: CONTACT lat: 50.93604 lon: 4.0355 facility: AZ Delta city: Brussels zip: 1070 country: Belgium name: C. Closset, Dr. role: CONTACT lat: 50.85045 lon: 4.34878 facility: Cliniques Universitaires Saint-Luc city: Brussels zip: 1070 country: Belgium name: F. Duhoux, Prof. role: CONTACT lat: 50.85045 lon: 4.34878 facility: Free University Brussels (VUB) city: Brussels zip: 1070 country: Belgium name: C. Fontaine, Dr. role: CONTACT lat: 50.85045 lon: 4.34878 facility: Institut Jules Bordet city: Brussels zip: 1070 country: Belgium name: E. De Azambuja, Prof. role: CONTACT lat: 50.85045 lon: 4.34878 hasResults: False |
<|newrecord|> nctId: NCT06369818 id: AnIt23-02 briefTitle: Correlation of Cardiac Output Determined by Echocardiography and Indirect Calorimetry in Critically Ill Patients in Cardiogenic Shock on Extracorporeal Circulatory Life Support overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-09 date: 2027-02 date: 2024-04-17 date: 2024-04-17 name: Universität Münster class: OTHER briefSummary: This observational study investigates whether the daily measured trend of cardiac output as evaluated by indirect calorimetry correlates with the same evaluated by transthoracic echocardiography. conditions: Cardiogenic Shock studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED measure: Correlation of t two methods of determining cardiac output (determined by transthoracic echocardiography and determined by indirect calorimetry sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Münster city: Münster zip: 48149 country: Germany name: Thilo von Groote, MD role: CONTACT phone: +49-251-47255 lat: 51.96236 lon: 7.62571 hasResults: False |
<|newrecord|> nctId: NCT06369805 id: 2021-00731 briefTitle: EVALUATION OF BLOOD BIOMARKER-BASED DIAGNOSTIC AID IN OUTPATIENTS SUFFERING FROM DEPRESSION overallStatus: COMPLETED date: 2021-06-02 date: 2022-11-17 date: 2022-11-17 date: 2024-04-17 date: 2024-04-17 name: Les Toises - Psychiatry and Psychotherapy Center class: OTHER briefSummary: This is an observational (non-interventional) study, carried out in an outpatient setting, which involves a blood sampling. The primary objective of this study is to confirm the association between the EDIT-B® editing signature and early unipolar or bipolar differentiation. Results of this research may provide an aid to early diagnosis and guide clinical practice towards individualized treatment. conditions: Depressive Disorder conditions: Bipolar Disorder conditions: Bipolar Depression studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 307 type: ACTUAL name: there is no intervention measure: Psychiatric symptomatology sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Les Toises - Psychiatry and Psychotherapy Center city: Lausanne zip: 1005 country: Switzerland lat: 46.516 lon: 6.63282 hasResults: False |
<|newrecord|> nctId: NCT06369792 id: 2020-00266 briefTitle: PROSPECTIVE EVALUATION OF BLOOD BIOMARKERS AS AN AID TO DIAGNOSTIC AND TREATMENT IN DRUG-NAIVE PATIENTS WITH DEPRESSION overallStatus: RECRUITING date: 2020-10-20 date: 2024-12-31 date: 2024-12-31 date: 2024-04-17 date: 2024-04-17 name: Les Toises - Psychiatry and Psychotherapy Center class: OTHER briefSummary: This is an observational (non-interventional) prospective study, carried out in drug-naïve outpatients who start a treatment with escitalopram, fluoxetine, sertraline or quetiapine. Five blood samples are collected (i.e. before initiating the drug, and then after 1, 2, 4 and 8 weeks of treatment). It does not affect the choice or the treatment dose. The primary objective of this study is to measure the association between the EDIT-B® editing signature and response to pharmacological treatment in drug-naïve patients. Results of this research could provide an aid to early diagnosis, optimize pharmacological treatment and guide clinical practice towards individualized treatment. conditions: Depressive Disorder conditions: Bipolar Disorder conditions: Bipolar Depression studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: psychiatric symptomatology measure: EDIT-B profiling sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Les Toises - Psychiatry and Psychotherapy Center status: RECRUITING city: Lausanne zip: 1005 country: Switzerland name: Aurélie Reymond-Delacrétaz, PhD role: CONTACT phone: +41584580580 email: [email protected] lat: 46.516 lon: 6.63282 hasResults: False |
<|newrecord|> nctId: NCT06369779 id: OTCS 36406866 briefTitle: Clinical Evaluation of a New Flowable and a New Sculptable Universal Bulk-fill Composite for Direct Restorative Treatment overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-12 date: 2030-12 date: 2024-04-17 date: 2024-04-17 name: Ivoclar Vivadent AG class: INDUSTRY briefSummary: The overall objective of this clinical investigation is to evaluate the clinical safety and performance of the new flowable composite TM Flow and the new sculptable composite TM Fill for restoration of class I and class II cavities. The fillings are assessed according to selected FDI criteria at baseline (7-10 days after placement of filling) and after 1, 6, 12, 24, 36 and 60 months. conditions: Class I or II Cavities in Premolars or Molars studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 65 type: ESTIMATED name: TM Fill and TM Flow measure: Postoperative hypersensitivity measure: evaluation of functional (e.g. fracture of the material and retention), biological (e.g. caries at restoration margins) and aesthetic (e.g. color match) properties of the restorations sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06369766 id: 2023-02144; ko23Papadopoulou4 briefTitle: REtinal Markers In Neuroinflammatory Diseases ("REMIND") overallStatus: RECRUITING date: 2024-01-31 date: 2028-12 date: 2029-02 date: 2024-04-17 date: 2024-04-17 name: University Hospital, Basel, Switzerland class: OTHER name: University of Basel briefSummary: The goal of this observational study, including patients with Multiple Sclerosis, patients with other neuroinflammatory diseases and healthy controls, is to determine the predictive value of retinal markers in predicting disease progression. Participants complete a questionnaire and undergo various non-invasive retinal routine clinical examinations. conditions: Multiple Sclerosis conditions: Neuroinflammatory Diseases studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: Optical coherence tomography (OCT) name: Static retinal vessel analyzer name: Dynamic retinal vessel analyzer name: Laser speckle flowgraphy system name: Questionnaire measure: Occurence of Progression Independent of Relapse Activity (PIRA) measure: Neuroaxonal loss in the retina (as marker of neurodegeneration in the CNS) measure: Neuroinflammation in the retina measure: Fixation instability (as marker of global neuronal dysfunction in the CNS) measure: Structural changes of the retinal vessels (as marker of systemic microvascular health) measure: (For a subgroup of participants) Functional/perfusional changes of the retinal vessels measure: Relative value of retinal markers for the prediction of PIRA compared to or combined with other biomarkers of neuroaxonal damage measure: Comparison of the examined retinal markers of Multiple Sclerosis patients with Healthy Controls and with patients with other neuroinflammatory diseases of the CNS measure: The relationship between neuroaxonal loss, functional deficits and vascular changes in Multiple Sclerosis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Basel, Department of Neurology status: RECRUITING city: Basel zip: 4031 country: Switzerland name: Athina Papadopoulou, PD Dr. med. role: CONTACT phone: +41 61 32 85704 email: [email protected] name: Athina Papadopoulou, PD Dr. med. role: PRINCIPAL_INVESTIGATOR lat: 47.55839 lon: 7.57327 hasResults: False |
<|newrecord|> nctId: NCT06369753 id: PR(AG)459/2023B briefTitle: Visible Abdominal Distension overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2025-05 date: 2025-07 date: 2024-04-17 date: 2024-04-17 name: Hospital Universitari Vall d'Hebron Research Institute class: OTHER briefSummary: Background. Abdominal distention is produced by an abnormal somatic postural tone. The authors developed an original biofeedback technique. In a randomized, placebo-controlled trial the authors demonstrated the superiority of biofeedback over placebo for the treatment of abdominal distention. However, the technique is technically complex and unpractical. |
Aim. To prove the efficacy of a noninstrumental biofeedback technique, transmitted by a standard training program, for the treatment of abdominal distension in different centers. |
Selection criteria. Episodes of visible abdominal distension. Intervention. Patients will be randomized into biofeedback and placebo groups. Three sessions of either biofeedback or placebo intervention will be performed during the first 3 weeks of the intervention period. |
Biofeedback: Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. In each center one operator will receive a standard training on how to deliver the noninstrumental biofeedback treatment. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period. |
Placebo: Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period. conditions: Irritable Bowel Syndrome conditions: Dyspepsia conditions: Functional Bloating studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 100 type: ESTIMATED name: Biofeedback name: Placebo measure: Visible abdominal distension measure: Sensation of abdominal pressure/fullness measure: Sensation of abdominal discomfort/pain measure: Follow-up after biofeedback sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Universitari Vall d'Hebron city: Barcelona zip: 08035 country: Spain lat: 41.38879 lon: 2.15899 hasResults: False |
<|newrecord|> nctId: NCT06369740 id: ENZ20-2024-INDIANAPOLIS briefTitle: Case and Use Scenario Study to Gain Knowledge on the User Needs for a Medical Device for Hemophilia A Monitoring overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-06-04 date: 2024-06-04 date: 2024-04-17 date: 2024-04-17 name: Enzyre B.V. class: INDUSTRY name: Indiana Hemophilia & Thrombosis Center briefSummary: This observational study consists of two parts. |
In part one, case scenario focus groups with hemophilia A patients and healthcare providers (HCPs) will be held. This parts aims to identify potential use scenarios of a point of care (POC) in vitro medical for patients with hemophilia A. The main questions it aims to answer are: |
* How is coagulation lab testing for patients with hemophilia A currently organized? |
* What is the interest and what are desired alternatives of a POC in-vitro diagnostic medical device for patients with hemophilia A? |
Part two of the study consists of a use scenario study in which patients with hemophilia A and HCPs will evaluate two types of non-functional mock-ups of a POC in vitro medical device. The main goal of this part is to evaluate the usability of the current prototypes of the POC device. conditions: Hemophilia A studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 102 type: ESTIMATED name: Case scenarios - questionnaire name: Case scenarios - Focus groups name: Use scenarios - Usability test name: Use scenarios - interview measure: Current management of Hemophilia A coagulation lab testing measure: Potential case scenarios for a point of care in-vitro diagnostic device for hemophilia A measure: Usability issues of the current POC in-vitro diagnostic device prototypes measure: User preferences for the point of care in-vitro diagnostic device measure: Problems with current Hemophilia A coagulation monitoring measure: Potential benefits of a POC device for home use, near-patient use or in clinic use sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Indiana Hemophilia & Thrombosis Center city: Indianapolis state: Indiana zip: 46260 country: United States lat: 39.76838 lon: -86.15804 hasResults: False |
<|newrecord|> nctId: NCT06369727 id: MOB015B-VI briefTitle: Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design acronym: RIPT overallStatus: COMPLETED date: 2017-10-15 date: 2018-02-15 date: 2018-02-15 date: 2024-04-17 date: 2024-04-17 name: Moberg Pharma AB class: INDUSTRY briefSummary: A Randomized, Controlled Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design To evaluate the sensitization potential conditions: Erythema studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE maskingDescription: NA- Safety study count: 250 type: ACTUAL name: MOB015B name: MOB015B vehicle name: Negative irritant solution of 0.9% saline measure: To determine the potential of MOB015B to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions. measure: To assess safety sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: TKL Research, Inc city: Fair Lawn state: New Jersey zip: 07410 country: United States lat: 40.94038 lon: -74.13181 hasResults: False |
<|newrecord|> nctId: NCT06369714 id: CHEC2023-296 briefTitle: Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children. acronym: ADHD overallStatus: RECRUITING date: 2023-02-24 date: 2025-02-24 date: 2025-02-24 date: 2024-04-17 date: 2024-04-17 name: Lei Lei, MD class: OTHER briefSummary: A multi-center, randomized controlled trial is being conducted to investigate the efficacy of a novel digital therapeutics (DTx) program that utilizes a cross-training approach between neurofeedback training and executive function training for pediatric patients (aged 6-12) diagnosed with ADHD. This gamified interactive program is designed to improve attention deficits and executive function impairments in pediatric patients with ADHD. It is delivered through an engaging iPad game in a home-based treatment format. Patients will be randomly assigned to one of three groups: medication alone, digital therapeutics alone, or a combination of both interventions. Subjects will undergo 30 treatment sessions over the 8-week period, with each session lasting 30 minutes. Investigators will reassess symptoms of ADHD, executive functions, and objective measures of attention at the end of the treatment. Additionally, questionnaires will be distributed to parents to gather their insights and feedback on the treatment approach. This innovative digital therapeutics approach is expected to improve ADHD symptoms individually and enhance therapeutic outcomes when used alongside conventional drug treatment regimens. conditions: Attention Deficit Disorder With Hyperactivity conditions: Executive Function Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 200 type: ESTIMATED name: Concerta name: Digital therapeutics measure: Swanson, Nolan, and Pelham IV Rating Scale measure: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for ADHD measure: Questionnaire-Children with Difficulties measure: Behavior Rating Inventory of Executive Function measure: Continuous Performance Test measure: Digital Cancellation Test sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD facility: Changzheng Hospital, Naval Medical University status: RECRUITING city: Shanghai state: Shanghai zip: 200003 country: China name: Yujiao Wang, MBBS role: CONTACT phone: 15021500051 email: [email protected] lat: 31.22222 lon: 121.45806 facility: Changhai Hospital, Naval Medical University status: RECRUITING city: Shanghai state: Shanghai zip: 200433 country: China name: Yuanhao Cai, MBBS role: CONTACT phone: 15001969690 email: [email protected] name: Yuanhao Cai, MBBS role: SUB_INVESTIGATOR name: Lei Lei, MD role: PRINCIPAL_INVESTIGATOR lat: 31.22222 lon: 121.45806 hasResults: False |
<|newrecord|> nctId: NCT06369701 id: C.2024.019 briefTitle: Effects Compressive Tissue Flossing on Lateral Elbow Tendinopathy in US Service Members overallStatus: RECRUITING date: 2024-02-13 date: 2024-05 date: 2024-06 date: 2024-04-17 date: 2024-04-17 name: Brooke Army Medical Center class: FED briefSummary: The purpose of this research study will be to assess the effects of a compressive tissue flossing (CTF) program on the symptoms of lateral elbow tendinopathy in United States service members. Dependent variables will be the Defense and Veteran's Pain Rating Scale (DVPRS), decrease their Patient-Rated Tennis Elbow Evaluation (PRTEE) score, increase their maximal grip strength in the affected upper extremity (UE). Measurements will be taken at baseline, immediately after the first CTF intervention, and at the 1-week follow-up, for a total of 3 measurements. conditions: Lateral Elbow Tendinopathy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Within-subjects repeated measures design primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: Compressive tissue floss band measure: Patient's report of pain on the Defense and Veteran's Pain Rating Scale measure: Patient-Rated Tennis Elbow Evaluation measure: Maximal grip strength in the affected upper extremity sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Brooke Army Medical Center status: RECRUITING city: Fort Sam Houston state: Texas zip: 78234 country: United States name: Carly R Cooper, PhD role: CONTACT phone: 210-808-2240 email: [email protected] name: Brian T Gregg, PhD role: CONTACT phone: (210) 808-2269 email: [email protected] name: John E Elam, DSc Fellow role: PRINCIPAL_INVESTIGATOR name: Carly R Cooper, PhD role: SUB_INVESTIGATOR name: Katelyn A Culley, DSc Fellow role: SUB_INVESTIGATOR name: Tara A Haugen, DSc Fellow role: SUB_INVESTIGATOR lat: 29.45746 lon: -98.4472 hasResults: False |
<|newrecord|> nctId: NCT06369688 id: Baqiyatallah University briefTitle: IDEAL SKIIN CARES Bundle to Prevent Pressure Injury acronym: IdealSkinCares overallStatus: NOT_YET_RECRUITING date: 2025-10-01 date: 2026-10-01 date: 2027-10-01 date: 2024-04-17 date: 2024-04-17 name: Baqiyatallah Medical Sciences University class: OTHER name: Tehran University of Medical Sciences name: Hamadan University of Medical Science name: Tabriz University of Medical Sciences briefSummary: The study will be a multi-center, triple-blinded, cluster randomized controlled trial (c-RCT) conducted with a three-arm parallel design and a 1:1:1 allocation ratio. The experimental groups will consist of two arms: the intervention group, where patients will receive training in relevant pressure injury care bundles, and the placebo group, where patients will receive training in an irrelevant topic like respiratory care. Both intervention and placebo groups will receive specialized pressure injury prevention (PIP) care bundle from trained wound specialist nurses (WSNs). The third arm will be the control group comprising patients who do not undergo any training course and will receive only routine standard care for PIP care bundle. The aim of c-RCT will be to compare the incidence of hospital-acquired pressure injury (HAPI) in the three study groups and to provide detailed evidence on the effect of the developed pressure injury care bundle, administered by WSNs on the development of HAPI in trained hospitalized patients, as opposed to those receiving routine standard care for PIP care bundle without training. conditions: Pressure Ulcer conditions: Pressure Injury conditions: Bed Sore conditions: Pressure Sore conditions: Decubitus Sore conditions: Decubitus Ulcer conditions: Skin Ulcer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: C-RCT will be conducted with a three-arm parallel design and a 1:1:1 allocation ratio. The experimental groups will consist of two arms: the intervention group and the placebo group. The third arm will be the control group. primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: In this placebo-controlled trial, patients will be blinded to their group allocations. Additionally, WSNs, who are trained for delivering special PIP care bundles, as well as nursing staff who are responsible for measuring wounds and collecting data, and data analyst, will also be blinded. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1620 type: ESTIMATED name: IDEAL SKIIN CARES bundles name: IDEAL SKIIN CARES bundles workshop name: Respiratory care workshop measure: Incidence of hospital-acquired pressure injury (HAPI) measure: Pressure Injury Stage measure: Patient participation in care measure: Healthcare costs measure: Self-report Patient participation in care sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06369675 id: MOB015B-V briefTitle: Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design acronym: CIPT overallStatus: COMPLETED date: 2017-10-19 date: 2017-11-14 date: 2017-11-14 date: 2024-04-17 date: 2024-04-17 name: Moberg Pharma AB class: INDUSTRY briefSummary: A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design To evaluate the irritation potential of MOB015B on normal skin. Single center, randomized, controlled, evaluator blinded, within-subject comparison study conditions: Erythema studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 45 type: ACTUAL name: MOB015B name: 0.2% SLS name: 0.9% Saline name: MOB015B vehicle measure: To determine the potential of MOB015B to cause skin irritation after repeated topical application to the healthy skin of humans under controlled conditions. measure: To assess safety sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: TKL Research, Inc city: Fair Lawn state: New Jersey zip: 07410 country: United States lat: 40.94038 lon: -74.13181 hasResults: False |
<|newrecord|> nctId: NCT06369662 id: SECI-CD155 id: SECI-IRB-IORG0006563-545 type: OTHER domain: Scientific Research Unit briefTitle: CD155 Expression in Acute Myeloid Leukemia overallStatus: ACTIVE_NOT_RECRUITING date: 2022-07-01 date: 2023-12-31 date: 2024-08-30 date: 2024-04-17 date: 2024-04-17 name: Assiut University class: OTHER briefSummary: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy. It is the most common form of acute leukemia among adults. In the United States, an estimated 19,940 people will be diagnosed with AML in 2020. |
CD155 expression was associated with an unfavorable prognosis in solid tumors such as colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma, as it correlated with tumor migration, development of metastases, tissue and lymph node invasion, relapse, and poorer survival. conditions: Acute Myeloid Leukemia studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 93 type: ACTUAL name: Flow cytometric immunophenotyping name: Complete blood count name: Bone marrow aspiration name: Cytogenetic testing name: FLT3-ITD using High resolution melting curve (HRM) analysis measure: CD155 expression level in AML patients sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: South Egypt Cancer Institute, Assiut University city: Assiut zip: 71111 country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False |
<|newrecord|> nctId: NCT06369649 id: COOLSENSE-1 briefTitle: Coolsense and Buzzy Use on Pain Score and Anxiety Level During Insulin Injection Application overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-08-31 date: 2025-12-31 date: 2024-04-17 date: 2024-04-17 name: Ankara Yildirim Beyazıt University class: OTHER briefSummary: This study aims to determine the effect of using Coolsense, which is created using the proven effect of cold application during insulin injection, and Buzzy, which is a combination of vibration and cold application, in reducing pain and anxiety in children diagnosed with Type 1 diabetes mellitus.This randomized controlled clinical study is planned to be conducted between 05.2024-12.2025 with 147 participants between the ages of 6-12. Participants will be divided into three groups according to the randomization method: buzzy group (n = 49), coolsense group (n = 49) and control group (n = 49). Participants in the Coolsense group will receive a cold application using the coolsense device for 5 seconds before the injection. Participants in the Buzzy group will be subjected to vibration and cold application 30-60 seconds before the procedure. Participants in the control group will continue the clinic's standard procedure. Changes in participants' pain score and fear level, heart rate, blood pressure, respiratory rate and oxygen saturation will be measured at three time points: immediately before and after the procedure. Data descriptive information form, application registration form, Facial Expressions Pain Scale (FPS-R) and Child Fear Scale (CFS) will be used. The collected data will be analyzed using SPSS 15 software. The main questions it aims to answer: |
* Does buzzy and coolsense application have an effect the pain score of children during the insülin injection? |
* Does buzzy and coolsense application have an effect the fear score of children during the insülin injection? |
* Does buzzy and coolsense application have an effect the heart rate of children during the insülin injection? |
* Does buzzy and coolsense application have an effect the oxygen saturation of children during the insülin injection? |
* Does buzzy and coolsense application have an effect the blood pressure of children during the insülin injection? |
* Does buzzy and coolsense application have an effect the respiratory rate of children during the insülin injection? conditions: Injection Fear conditions: Injection Site Coldness conditions: Pain conditions: Type 1 Diabetes Mellitus conditions: Pediatric Disease conditions: Nurse's Role studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Single blinding (participants) will be used in the research and the researchers will not have information about the other group. |
While applying both scales, care will be taken to ensure that children, parents and observers do not see each other's evaluations and are not influenced by each other. In this way, the child, parent and independent observer will score blindly before and after the procedure. whoMasked: PARTICIPANT count: 147 type: ESTIMATED name: Coolsense and Buzzy measure: Faces Pain Scale- Revised (FPS-R) measure: Children's Fear Scale (CFS) measure: Heart rate measure: Oxygen saturation measure: Respiratory rate measure: Blood pressure sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD hasResults: False |
<|newrecord|> nctId: NCT06369636 id: myucesu briefTitle: Comparison of El-Ganzouri Risk Index and Airway Ultrasonographic Evaluation in Thyroid Surgery overallStatus: COMPLETED date: 2023-06-01 date: 2023-10-31 date: 2024-01-28 date: 2024-04-17 date: 2024-04-17 name: Ankara City Hospital Bilkent class: OTHER briefSummary: The primary purpose of this prospective observational study was to compare these tests used to predict difficult intubation in patients undergoing thyroid surgery. Secondarily; By comparing these tests, we aim to find the test that best predicts difficult intubation and to determine the incidence of difficult intubation in patients who will undergo thyroid surgery. conditions: Thyroid Surgery conditions: Difficult Intubation studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 120 type: ACTUAL name: Thyroid Surgery measure: Compare EGRI and airway ultrasonographic parameters measure: Find which is the best test predicts difficult intubation measure: Finding the incidence of difficult intubation in thyroid surgery sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Bilkent City Hospital city: Ankara state: Çankaya zip: 06800 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False |
<|newrecord|> nctId: NCT06369623 id: IRB2023-00466 briefTitle: Monetary Incentive Delay Task for Probing Reward-related Neural Processes acronym: MID overallStatus: RECRUITING date: 2024-04-06 date: 2028-11-30 date: 2028-11-30 date: 2024-04-17 date: 2024-04-17 name: Stony Brook University class: OTHER briefSummary: 150 males and 150 females ages 14-17 years-old will be enrolled in an observational, longitudinal study. There are three planned in-person visits: a baseline assessment, an 18-month follow-up, and a 36-month follow-up. The in-person visits will include assessment of substance use and other individual differences (e.g., reward function, psychiatric history), neuromelanin-sensitive MRI, as well as functional brain activation collected while the participant is at rest (resting-state fMRI) and while the participant completes a Monetary Incentive Delay task. Subjects will also be asked to complete past 90-day substance use assessments remotely every 90 days for 36 months. conditions: Adolescent Development studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 300 type: ESTIMATED name: Monetary Incentive Delay Task measure: Functional Brain Activation from Monetary Incentive Delay Task sex: ALL minimumAge: 14 Years maximumAge: 17 Years stdAges: CHILD facility: Stony Brook Medicine status: RECRUITING city: Stony Brook state: New York zip: 11794 country: United States name: Greg Perlman, PhD role: CONTACT phone: 631-638-1922 email: [email protected] name: Roman Kotov, PhD role: CONTACT name: Greg Perlman, PhD role: PRINCIPAL_INVESTIGATOR lat: 40.92565 lon: -73.14094 hasResults: False |
<|newrecord|> nctId: NCT06369610 id: GMROA2256 id: NCI-2024-03020 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 22-012591 type: OTHER domain: Mayo Clinic Institutional Review Board id: GMROA2256 type: OTHER domain: Mayo Clinic in Arizona briefTitle: Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer overallStatus: RECRUITING date: 2024-04-22 date: 2027-04-22 date: 2027-04-22 date: 2024-04-17 date: 2024-04-24 name: Mayo Clinic class: OTHER briefSummary: This phase II trial tests how well risk based de-escalated hormone therapy (i.e., fewer treatments) with radiation works in treating patients with prostate cancer. Androgen deprivation therapy (ADT), such as gonadotropin-releasing hormone analogs (LHRH) and abiraterone acetate (Zytiga), lower the amount of the male hormone, testosterone, made by the body. This may help kill or stop the growth of tumor cells that need testosterone to grow. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Research has shown that long-term ADT is beneficial for patients with high-risk prostate cancer. However, there are few studies that determine ADT treatment based on risk factors. Giving risk based de-escalated ADT with radiation therapy may be as effective as giving more ADT in treating high-risk prostate cancer. conditions: Oligometastatic Prostate Carcinoma conditions: Prostate Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 64 type: ESTIMATED name: Abiraterone Acetate name: Biospecimen Collection name: Computed Tomography name: Gonadotropin-releasing Hormone Analog name: Magnetic Resonance Imaging name: Positron Emission Tomography name: Questionnaire Administration name: Radiation Therapy measure: Hormonal domain scores sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Arizona status: RECRUITING city: Scottsdale state: Arizona zip: 85259 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: [email protected] name: Carlos E. Vargas, M.D. role: PRINCIPAL_INVESTIGATOR lat: 33.50921 lon: -111.89903 hasResults: False |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.